STORY FROM: Drugs & Medical Devices

Journal Top Ten


photo-6

photo-7 Related Drug: Avandia

Article: "Severe Cholestatic Hepatitis Caused by Thiazolidinediones: Risks Associated with Substituting Rosiglitazone for Troglitazone"

Summary: The association between troglitazone and severe hepatotoxicity led to the drug's removal from the U.S. market in 2000. Rosiglitazone is currently marketed as a safer alternative for the treatment of type 2 diabetes mellitus. This is a case report of a 56-year old woman who was diagnosed with thiazolidinedione-induced cholestatic hepatitis after ingesting 8 mg/day of rosiglitazone. She had previously developed mild hepatotoxicity while taking troglitazone. Liver function tests performed after the switch showed moderate increases in serum alkaline ...



Registered User Login

Username

Password

True